Gravity Branding names Novartis’ Vijoice®
Gravity Branding recently announced its success naming Vijoice® (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
On April 5, 2022, the FDA granted accelerated approval to alpelisib (brand name Vijoice®) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy.
Vijoice® is a fabricated name that can be regarded as optimistic and life affirming, but essentially, represents an empty vessel poised to be filled with relevant brand qualities. In addition to Gravity’s pharmaceutical naming experience, the agency works alongside Novartis and its technology partners on branding ground-breaking digital therapeutics.
The bar for international pharmaceutical naming is high. In addition to clearing international health agency scrutiny and trademark review, other key considerations include avoiding confusion with proprietary and non-proprietary drug or medical technology names, any drug performance claims not substantiated by the clinical research process, and reference to religious and any inappropriate international idiomatic expressions. Ensuring names are reasonably easy to pronounce in all markets is also important.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
